{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T21:48:09Z","timestamp":1696369689291},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/ppo.0b013e31826c57f1","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T21:40:28Z","timestamp":1348263628000},"page":"439-444","source":"Crossref","is-referenced-by-count":4,"title":["Management of the Cutaneous Peripheral T-Cell Lymphomas"],"prefix":"10.1097","volume":"18","author":[{"given":"Michael Youngjun","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210203","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.23144","article-title":"The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.","volume":"87","author":"Armitage","year":"2012","journal-title":"Am J Hematol"},{"key":"R2-10-20210203","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-5-24","article-title":"Novel therapeutic agents for cutaneous T-cell lymphoma.","volume":"5","author":"Jain","year":"2012","journal-title":"J Hematol Oncol"},{"key":"R3-10-20210203","first-page":"75","article-title":". Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.","volume":"4","author":"Li","year":"2012","journal-title":"Cancer Manag Res"},{"key":"R4-10-20210203","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminoncol.2012.01.010","article-title":". Recent advances in the management of cutaneous lymphomas.","volume":"39","author":"Belloni","year":"2012","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"R5-10-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.0303-6987.2006.00494.x","article-title":"Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC.","volume":"33","author":"Willemze","year":"2006","journal-title":"J Cutan Pathol"},{"key":"R7-10-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/path.1711720110","article-title":"6. Beljaards RC, Meijer CJ, Van der Putte SC, et al.. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma.","volume":"172","year":"1994","journal-title":"J Pathol"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1365-2133.2005.06905.x","article-title":"The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants.","volume":"153","author":"Slater","year":"2005","journal-title":"Br J Dermatol"},{"key":"R9-10-20210203","first-page":"146","article-title":"The skin as an immune organ.","volume":"160","author":"Salmon","year":"1994","journal-title":"West J Med"},{"key":"R10-10-20210203","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.jid.5700199","article-title":". A novel method for the isolation of skin resident T cells from normal and diseased human skin.","volume":"126","author":"Clark","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R11-10-20210203","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF00424268","article-title":". Predominance of memory T cells (CD4, CDw29) over naive T cells (CD4, CD45R) in both normal and diseased human skin.","volume":"281","author":"Bos","year":"1989","journal-title":"Arch Dermatol Res"},{"key":"R12-10-20210203","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00372006","article-title":". Skin-homing T lymphocytes: detection of cutaneous lymphocyte-associated antigen (CLA) by HECA-452 in normal human skin.","volume":"285","author":"Bos","year":"1993","journal-title":"Arch Dermatol Res"},{"key":"R13-10-20210203","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ni1240","article-title":"Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics.","volume":"6","author":"Bromley","year":"2005","journal-title":"Nat Immunol"},{"key":"R14-10-20210203","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.4049\/jimmunol.176.7.4431","article-title":". The vast majority of CLA T cells are resident in normal skin.","volume":"176","author":"Clark","year":"2006","journal-title":"J Immunol"},{"key":"R15-10-20210203","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":". Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"key":"R16-10-20210203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance.","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"R17-10-20210203","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/jid.2009.247","article-title":"Skin-resident T cells: the ups and downs of on site immunity.","volume":"130","author":"Clark","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R18-10-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":". Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"R19-10-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2011.03.005","article-title":"Molecular aspects of epithelial gammadelta T cell regulation.","volume":"32","author":"Witherden","year":"2011","journal-title":"Trends Immunol"},{"key":"R20-10-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ni.2240","article-title":". Body-barrier surveillance by epidermal gammadelta TCRs.","volume":"13","author":"Chodaczek","year":"2012","journal-title":"Nat Immunol"},{"key":"R21-10-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0625.1998.tb00312.x","article-title":"CD8 cytolytic T lymphocytes and the skin.","volume":"7","author":"De Panfilis","year":"1998","journal-title":"Exp Dermatol"},{"key":"R22-10-20210203","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/1523-1747.ep12470172","article-title":". The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin.","volume":"88","author":"Bos","year":"1987","journal-title":"J Invest Dermatol"},{"key":"R23-10-20210203","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2009.02.035","article-title":". Primary cutaneous aggressive epidermotropic CD8 T-cell lymphoma.","volume":"62","author":"Gormley","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R24-10-20210203","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood-2006-02-002873","article-title":"IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin.","volume":"109","author":"Clark","year":"2007","journal-title":"Blood"},{"key":"R25-10-20210203","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1084\/jem.20071190","article-title":". Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells.","volume":"205","author":"Clark","year":"2008","journal-title":"J Exp Med"},{"key":"R26-10-20210203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semdp.2011.03.003","article-title":"Follicular helper T cells: implications in neoplastic hematopathology.","volume":"28","author":"Gaulard","year":"2011","journal-title":"Semin Diagn Pathol"},{"key":"R27-10-20210203","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/ehm.11.37","article-title":". Peripheral T-cell lymphoma classification: the matter of cellular derivation.","volume":"4","author":"Piccaluga","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"R28-10-20210203","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrclinonc.2009.169","article-title":". Gamma-delta T-cell lymphomas.","volume":"6","author":"Tripodo","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"R29-10-20210203","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":". Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"R30-10-20210203","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archderm.136.8.1024","article-title":". gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study.","volume":"136","author":"Toro","year":"2000","journal-title":"Arch Dermatol"},{"key":"R31-10-20210203","first-page":"1065","article-title":". Cutaneous gammadelta T-cell lymphoma.","volume":"7","author":"Koch","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"R32-10-20210203","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","article-title":". Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma.","volume":"101","author":"Toro","year":"2003","journal-title":"Blood"},{"key":"R33-10-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000327932","article-title":". Two atypical cases of cutaneous gammadelta T-cell lymphomas.","volume":"222","author":"Caudron","year":"2011","journal-title":"Dermatology"},{"key":"R34-10-20210203","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1111\/j.1365-2230.2009.03296.x","article-title":". Cutaneous gammadelta T-cell lymphoma treated with retinoid and narrowband ultraviolet B.","volume":"34","author":"Nakashima","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"R35-10-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","article-title":". Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.","volume":"12","author":"Mehta","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R36-10-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3816\/CLM.2008.n.005","article-title":"Cutaneous gammadelta T-cell lymphoma treated with radiation and denileukin diftitox.","volume":"8","author":"Vidulich","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"R37-10-20210203","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ajh.21180","article-title":". Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gammadelta T-cell lymphoma and occult cirrhosis.","volume":"83","author":"Avarbock","year":"2008","journal-title":"Am J Hematol"},{"key":"R38-10-20210203","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1346-8138.2010.00998.x","article-title":". Primary cutaneous gammadelta-T-cell lymphoma treated with low-dose methotrexate and narrowband ultraviolet B irradiation: report of a case with testicular involvement.","volume":"38","author":"Fujii","year":"2011","journal-title":"J Dermatol"},{"key":"R39-10-20210203","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archophthalmol.2011.317","article-title":". Cutaneous gammadelta T-cell lymphoma with bilateral ocular and adnexal involvement.","volume":"129","author":"Shunmugam","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R41-10-20210203","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0002-9440(10)65144-9","article-title":". Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.","volume":"155","author":"Berti","year":"1999","journal-title":"Am J Pathol"},{"key":"R42-10-20210203","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/cncr.11107","article-title":". Cytotoxicnatural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop.","volume":"97","author":"Santucci","year":"2003","journal-title":"Cancer"},{"key":"R43-10-20210203","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":". WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R45-10-20210203","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMcpc0706687","article-title":"Case records of the Massachusetts General Hospital. Case 38-2007. A 44-year-old woman with generalized, painful, ulcerated skin lesions.","volume":"357","author":"Liu","year":"2007","journal-title":"N Engl J Med"},{"key":"R46-10-20210203","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0190-9622(90)70074-R","article-title":"Cutaneous T cell lymphoma with suppressorcytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes.","volume":"22","author":"Agnarsson","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"R47-10-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000087025","article-title":". Fatal CD8 epidermotropic cytotoxic primary cutaneous T-cell lymphoma with multiorgan involvement.","volume":"211","author":"Marzano","year":"2005","journal-title":"Dermatology"},{"key":"R48-10-20210203","first-page":"253","article-title":". Cutaneous CD8 epidermotropic cytotoxic T-cell lymphoma with aggressive course (translated from French).","volume":"133","author":"Poszepczynska-Guigne","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"R49-10-20210203","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11899-007-0033-z","article-title":"Management of advanced-stage peripheral T-cell lymphomas.","volume":"2","author":"Kimby","year":"2007","journal-title":"Curr Hematol Malig Rep"},{"key":"R50-10-20210203","first-page":"441","article-title":". Primary cutaneous aggressive epidermotropic CD8 T-cell lymphoma with a CD15()CD30(-) phenotype.","volume":"17","author":"Yoshizawa","year":"2007","journal-title":"Eur J Dermatol"},{"key":"R51-10-20210203","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ajh.21231","article-title":". CD8 cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.","volume":"83","author":"Gopaluni","year":"2008","journal-title":"Am J Hematol"},{"key":"R52-10-20210203","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1111\/j.1365-2230.2009.03754.x","article-title":". Aggressive epidermotropic cutaneous CD8 (Bertis) lymphoma.","volume":"35","author":"Webber","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"R53-10-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0b013e31818e52fe","article-title":". Primary cutaneous CD4 smallmedium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers.","volume":"33","author":"Rodriguez Pinilla","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R54-10-20210203","first-page":"717","article-title":"Could follicular helper T-cells play a role in primary cutaneous CD4 smallmedium-sized pleomorphic T-cell lymphomas J Cutan Pathol.","volume":"36","author":"Ferenczi","year":"2009","journal-title":""},{"key":"R55-10-20210203","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/DAD.0b013e31819f19bb","article-title":". Primary cutaneous CD4 small-medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance A study of 136 cases.","volume":"31","author":"Beltraminelli","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"R56-10-20210203","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1200\/JCO.2008.16.1307","article-title":". Primary cutaneous smallmedium CD4 T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome.","volume":"26","author":"Garcia-Herrera","year":"2008","journal-title":"J Clin Oncol"},{"key":"R57-10-20210203","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/modpathol.2008.40","article-title":". Primary cutaneous CD4-positive smallmedium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.","volume":"21","author":"Grogg","year":"2008","journal-title":"Mod Pathol"},{"key":"R58-10-20210203","first-page":"389","article-title":"Primary cutaneous small- to medium-sized CD4 pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category.","volume":"12","author":"Williams","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"R59-10-20210203","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1529-8019.2010.01372.x","article-title":". Therapeutic hotline: primary cutaneous CD4 smallmedium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide.","volume":"23","author":"Wawrzycki","year":"2010","journal-title":"Dermatol Ther"},{"key":"R60-10-20210203","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":". Peripheral T-cell lymphoma.","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"R61-10-20210203","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":". Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"R62-10-20210203","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":". Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"R64-10-20210203","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":". Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"R65-10-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/era.11.4","article-title":"New drug therapies in peripheral T-cell lymphoma.","volume":"11","author":"Howman","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"R66-10-20210203","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/157489211793980051","article-title":"Novel systemic drugs for cutaneous T-cell lymphoma.","volume":"6","author":"Lech-Maranda","year":"2011","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"R67-10-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2141.2011.08620.x","article-title":". Alemtuzumab-resistant Sezary syndrome responding to zanolimumab.","volume":"154","author":"Alexandroff","year":"2011","journal-title":"Br J Haematol"},{"key":"R68-10-20210203","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"F, Radford J, Relander T, et al.. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.","volume":"150","year":"2010","journal-title":"Br J Haematol"},{"key":"R69-10-20210203","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/14712598.2012.670216","article-title":"Brentuximab vedotin in systemic T-cell lymphoma.","volume":"12","author":"Oki","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"R70-10-20210203","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":". Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0b013e31826c57f1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:26:45Z","timestamp":1620970005000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201209000-00010"}},"subtitle":["When Subtypes Matter"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31826c57f1","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}